BridgeMD
New treatment option for Acute Myocardial Infarction
Official title SUBDIMA: Subclinical Depression in Acute Myocardial Infarction (SUBDIMA25)
ClinicalTrials.gov ID: NCT07492537
What this study is testing
- What it's testing
- This is an exploratory, prospective, non-profit study (SUBDIMA) designed to investigate the prevalence and potential prognostic significance of subclinical depression in patients admitted with a first acute myocardial infarction (AMI). Subclinical depression refers to the presence of mild depressive symptoms (PHQ-9 score 5-9) that do not meet DSM-5 TR criteria for major depressive disorder but may still be clinically relevant.
- Time commitment: about 12 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years
- Hospital admission for first acute myocardial infarction (STEMI or NSTEMI) within 7 days from the index event
- PHQ-9 administered at screening
- Mini Mental State Examination (MMSE) score ≥26
- Written informed consent obtained
You likely can't join if
- Previous history of acute myocardial infarction
- Diagnosis of major depression according to DSM-5 TR criteria
- Severe cognitive impairment (MMSE \<26)
- Severe comorbidities with expected survival \<12 months
- Inability to participate in scheduled follow-up assessments
- Refusal or inability to provide informed consent
See the full eligibility criteria
- Age ≥18 years
- Hospital admission for first acute myocardial infarction (STEMI or NSTEMI) within 7 days from the index event
- PHQ-9 administered at screening
- Mini Mental State Examination (MMSE) score ≥26
- Written informed consent obtained
- Previous history of acute myocardial infarction
- Diagnosis of major depression according to DSM-5 TR criteria
- Severe cognitive impairment (MMSE \<26)
- Severe comorbidities with expected survival \<12 months
- Inability to participate in scheduled follow-up assessments
- Refusal or inability to provide informed consent
- Concurrent participation in other treatment clinical studies that could interfere with study outcomes
The study team makes the final eligibility decision.
Where it's taking place
- Roma, Italia, Italy
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Roma, Italia, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.